Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans Hagberg

Showing results (11-20 of 43) with videos related to

Pageof 5
Sort By:
Acta Oncologica (Stockholm, Sweden)|May 29, 2014
The response to vaccination against influenza A(H1N1) 2009, seasonal influenza and Streptococcus pneumoniae in adult outpatients with ongoing treatment for cancer with and without rituximabAke Berglund, Linda Willén, Lina Grödeberg, et al.
Leukemia Research|December 21, 2004
Heterogeneous somatic hypermutation status confounds the cell of origin in hairy cell leukemiaMia Thorsélius, Sarah H Walsh, Ulf Thunberg, et al.
Acta Radiologica (Stockholm, Sweden : 1987)|April 19, 2011
Whole-body diffusion-weighted imaging compared with FDG-PET/CT in staging of lymphoma patientsGoran Abdulqadhr, Daniel Molin, Gunnar Aström, et al.
British Journal of Haematology|May 16, 2020
The simplified follicular lymphoma PRIMA-prognostic index is useful in patients with first-line chemo-free rituximab-based therapyEva Kimby, Sandra Lockmer, Harald Holte, et al.
Acta Oncologica (Stockholm, Sweden)|January 14, 2017
Population-based experience on primary central nervous system lymphoma 2000-2012: the incidence is increasingGunilla Enblad, Gustaf Martinsson, Eva Baecklund, et al.
Blood|April 9, 2004
A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomasGunilla Enblad, Hans Hagberg, Martin Erlanson, et al.
Anesthesiology|August 2, 2007
Immunoglobulin E antibodies to rocuronium: a new diagnostic toolDidier G Ebo, Lennart Venemalm, Chris H Bridts, et al.
Blood|January 18, 2003
CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trialEva Osby, Hans Hagberg, Stein Kvaløy, et al.
Blood|January 25, 2003
Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndromeJeanette Lundin, Hans Hagberg, Roland Repp, et al.
British Journal of Haematology|July 16, 2010
Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphomaFrancesco d'Amore, John Radford, Thomas Relander, et al.
Pageof 5

Showing results (11-20 of 43) with videos related to

Sort By:
Pageof 5
Acta Oncologica (Stockholm, Sweden)|May 29, 2014
The response to vaccination against influenza A(H1N1) 2009, seasonal influenza and Streptococcus pneumoniae in adult outpatients with ongoing treatment for cancer with and without rituximabAke Berglund, Linda Willén, Lina Grödeberg, et al.
Leukemia Research|December 21, 2004
Heterogeneous somatic hypermutation status confounds the cell of origin in hairy cell leukemiaMia Thorsélius, Sarah H Walsh, Ulf Thunberg, et al.
Acta Radiologica (Stockholm, Sweden : 1987)|April 19, 2011
Whole-body diffusion-weighted imaging compared with FDG-PET/CT in staging of lymphoma patientsGoran Abdulqadhr, Daniel Molin, Gunnar Aström, et al.
British Journal of Haematology|May 16, 2020
The simplified follicular lymphoma PRIMA-prognostic index is useful in patients with first-line chemo-free rituximab-based therapyEva Kimby, Sandra Lockmer, Harald Holte, et al.
Acta Oncologica (Stockholm, Sweden)|January 14, 2017
Population-based experience on primary central nervous system lymphoma 2000-2012: the incidence is increasingGunilla Enblad, Gustaf Martinsson, Eva Baecklund, et al.
Blood|April 9, 2004
A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomasGunilla Enblad, Hans Hagberg, Martin Erlanson, et al.
Anesthesiology|August 2, 2007
Immunoglobulin E antibodies to rocuronium: a new diagnostic toolDidier G Ebo, Lennart Venemalm, Chris H Bridts, et al.
Blood|January 18, 2003
CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trialEva Osby, Hans Hagberg, Stein Kvaløy, et al.
Blood|January 25, 2003
Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndromeJeanette Lundin, Hans Hagberg, Roland Repp, et al.
British Journal of Haematology|July 16, 2010
Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphomaFrancesco d'Amore, John Radford, Thomas Relander, et al.
Pageof 5